Gemina Laboratories Ltd. (GLABF) Stock Price & Analysis
Gemina Laboratories Ltd. (GLABF) — price $0.05 (0.00%), as of the Nov 19, 2026 trading session; market cap $3.83M.
Educational signal · not a buy or sell recommendation · How to read this
Gemina Laboratories Ltd. · GLABF
Gemina Laboratories Ltd. is a Canadian biotechnology company focused on the research, development, and commercialization of in-vitro diagnostics.
Price as of Nov 19, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.05 | |
| Change on the day | 0.00% | |
| 52-week range | $0.0375 – $0.3439 | |
| Market capitalisation | $3.83M | |
| Shares traded on the day | 244.0K |
Price & events
Other perspectives
Council score for Gemina Laboratories (GLABF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Gemina Laboratories (GLABF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Gemina Laboratories Ltd. (GLABF) is the company analyzed here. It employs 6 people and is led by Robert Crandall Greene. In Q4 FY2025 it reported revenue of C$10,607 and net income of -C$831,427. The market values it at $3.83M.
What do the latest results show for Gemina Laboratories (GLABF)?
Short answer · as of
The most recent reported quarter, Q4 FY2025, carried revenue of C$10,607.
Quarterly income statement — 2 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2025 | C$10,607 | -C$831,427 | -C$0.01 (diluted) |
| Q1 FY2025 | C$10,878 | -C$760,833 | -C$0.01 (diluted) |
What are the financial strengths and risks for Gemina Laboratories (GLABF)?
Short answer · as of
The distress and quality screens read Altman Z -29.16 · Piotroski F 4. Trailing ratios: ROE 15.0% · ROA -67.3% · current ratio 0.01 · earnings yield -16.3% · free-cash-flow yield 0.1%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held GLABF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported GLABF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Common Questions About GLABF
These answers are editorial: 1 of these 8 answers is drawn from the GLABF research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is GLABF a good stock to buy?
Stock Expert AI does not rate GLABF buy, sell or hold. Gemina Laboratories Ltd. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the GLABF stock price today?
The last price recorded for Gemina Laboratories Ltd. (GLABF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks associated with investing in GLABF, particularly given its OTC listing?
Investing in GLABF carries significant risks, compounded by its 'OTC Other' listing and 'Unknown' disclosure status. Financially, the company exhibits extremely negative profit and gross margins, indicating substantial ongoing losses and a high cash burn rate, which raises concerns about its long-term financial viability without significant capital infusions.
What are the key factors to evaluate for GLABF?
Evaluate GLABF on fundamentals, analyst consensus, and risk factors. The absence of a dividend yield indicates that the company is reinvesting any capital back into operations or is not yet profitable enough to distribute earnings to shareholders. Not financial advice.
How frequently does GLABF data refresh on this page?
GLABF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven GLABF's recent stock price performance?
Gemina Laboratories Ltd. (GLABF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary novel surface functionalization chemistries for enhanced diagnostics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GLABF overvalued or undervalued right now?
Gemina Laboratories Ltd. (GLABF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research GLABF before investing?
Before investing in Gemina Laboratories Ltd. (GLABF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 13 figures on this page — 8 from Financial Modeling Prep (FMP) and 5 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com